Cancer Cure & Mice?

June 21, 2011 by staff 

Cancer Cure & Mice?Cancer Cure & Mice?, An international team of researchers used a human vaccine to treat prostate tumors in mice without side effects. Richard vile Ph.D., study leader and immunologist at the Mayo Clinic, along with Alan Melcher, Ph.D., and Peter Selby, Ph.D., both of the Center for Clinical Cancer Research UK, University of St. James’ Hospital have developed a cure for prostate cancer in mice that also shows promise for other cancers and melanoma as well.

Scientists have tried to achieve this in the past, but are hampered by the impossibility of isolating a diverse collection of antigens on tumor cells. This causes tumors to mutate and survive the body’s immune system.

However, vile and his team were able to overcome this first gathering part of the genetic code of human prostate tissue in a complementary DNA (cDNA) library. The cDNA was placed in a multitude of vesicular stomatitis virus (VSV), which was grown. They were given to mice as a vaccine via various intravenous injections.

Tumors have a unique “fingerprint” called an antigen, which triggers an immune response through a molecular tag of the protein. For the liberation of the human vaccine for prostate cancer antigens in the mutant VSV vector, mice T cells are capable of launching an attack. The animals’ immune systems then became familiar with the antigens expressed on the virus after being exposed to the virus mutated, and has created a potent immune response. This attacked the prostate tumors.

Immunotherapy research Vil those of others, as it made use of viruses as vectors for cDNA libraries. This eliminates the problem of isolation of antigens on tumor cells, offering an in-depth profile of the cancer.

“Nobody really knows how many antigens the immune system is best seen in tumor cells,” said Vil. “In expressing these proteins in highly immunogenic virus, which increased its visibility in the immune system. The immune system now thinks it is being invaded by the virus, which are the expression of cancer-related antigens to be eliminated.” Clinical trials are expected to begin within two years

Report to Team

Please feel free to send if you have any questions regarding this post , you can contact on

Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.


Comments are closed.